VN-0102
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 21, 2025
Comparative long-term follow-up study of persistence of immunity after JVC-001 measles, mumps, and rubella vaccination in Japanese children.
(PubMed, Hum Vaccin Immunother)
- "The results suggested that protective serum antibodies are maintained until the second dose of MMR vaccine is administered in a Japanese pediatric population. Trial registration: jRCTs031230590."
Clinical • Journal • Infectious Disease • Measles • Mumps • Pediatrics • Rubella
February 08, 2025
Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children.
(PubMed, Vaccine)
- "Although the non-inferiority of JVC-001 to currently approved vaccines was not demonstrated for the mumps component, clinical significance and consistent efficacy were indicated. Vaccine titer did not affect immunogenicity. JVC-001 is expected to have a lower risk of aseptic meningitis to currently approved vaccines and raised no new safety signals emerged."
Head-to-Head • Journal • CNS Disorders • Infectious Disease • Measles • Mumps • Rubella
June 22, 2024
Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5-6 years.
(PubMed, J Infect Chemother)
- "The second MMR vaccination with JVC-001 demonstrated sufficient antibody coverage against all three viruses; the safety profile was tolerable."
Journal • P3 data • Infectious Disease • Measles • Mumps • Rubella
February 07, 2019
Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
(PubMed, Hum Vaccin Immunother)
- "There was no apparent difference in the incidence of AEs between JVC-001 and the control groups. JVC-001 is safe and induces effective immunogenicity against measles, mumps, and rubella compared with the currently marketed vaccines in Japan."
Clinical • Journal • P1/2 data
1 to 4
Of
4
Go to page
1